In advanced forms of lymphoma, an avalanche of new data with chimeric antigen receptor (CAR) T cells was presented at the 2021 annual meeting of the American Society of Hematology (ASH), offering clinicians key guidance on safety and efficacy.
Coupled with new findings on promising new “off-the-shelf,” allogeneic targeted agents that avoid some of the logistical challenges of obtaining autologous CAR T cells for infusions, the ASH meeting yielded important information for